Ali Yalçındağ
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Yalçındağ has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Fatma Uçar
Department of Biochemistry, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
3 shared publications - Fatih Yay
Clinical Biochemistry Laboratory, Nigde Omer Halisdemir University Training and Research Hospital, Nigde, Turkey
2 shared publications - Gamze Erzin
Institute of Health Sciences, Interdisciplinary Neuroscience Department, Ankara University, Ankara, Türkiye.
2 shared publications - Sema Hepşen
Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Türkiye
2 shared publications - Sibel Örsel
Department of Psychiatry, Ankara Etlik City Hospital, Ankara, Türkiye
2 shared publications - A. Ozen Akyurek
VENTURA Software Inc. , Ankara , Türkiye
1 shared publication
Latest Publications
- Open Access
- 22 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7365
The Relationship Between Serum Vitamin D Levels and the First-Attempt Success of the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo (PC-BPPV)
Background/Objectives: Vitamin D deficiency has been associated with the occurrence and recurrence of benign paroxysmal positional vertigo (BPPV), but its influence on the immediate success of canalith repositioning maneuvers remains uncertain. This study investigated the relationship between serum vitamin D levels and the first-attempt success of the Epley maneuver in patients with posterior canal BPPV (PC-BPPV). Methods: This prospective observational study included 140 consecutive adults with objectively confirmed unilateral PC-BPPV. Serum 25-hydroxyvitamin D levels were measured at presentation before treatment. All patients underwent a standardized Epley maneuver. First-attempt success was defined as complete resolution of positional vertigo and disappearance of positional nystagmus on the Dix–Hallpike test at the one-week follow-up visit. Serum vitamin D levels were analyzed both as a continuous variable and according to laboratory reference ranges: deficiency (p = 0.079), a difference that did not reach statistical significance. In unadjusted exploratory analyses, patients with first-attempt success had significantly higher median serum vitamin D levels than those with treatment failure (52.2 [IQR, 30.0–68.4] vs. 36.8 [IQR, 21.3–66.1] nmol/L, p = 0.029), and success rates numerically increased across the three-tier classification (46.1%, 62.2%, 59.3%), without a clear dose–response pattern, neither the overall comparison (p = 0.208) nor pairwise subgroup comparisons reaching statistical significance. In a multivariable model adjusting for age, sex, and month of enrolment, vitamin D remained independently, though modestly, associated with first-attempt success (adjusted OR 1.14 per 10 nmol/L, 95% CI 1.00–1.29). Conclusions: The pre-specified primary comparison of first-attempt Epley maneuver success between vitamin D-deficient and non-deficient patients did not reach statistical significance, although the point estimate favored higher success in the non-deficient group (OR 1.83, 95% CI 0.93–3.59). An exploratory, initially unadjusted analysis suggested a positive, modest association between serum vitamin D as a continuous variable and first-attempt success; this association persisted after multivariable adjustment (adjusted OR 1.14, 95% CI 1.00–1.29) but did not follow a clear dose–response pattern across categorical vitamin D thresholds. These findings should be regarded as hypothesis-generating rather than establishing a definitive prognostic role for vitamin D, and larger, adequately powered multicenter studies are needed to confirm them.
- 22 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7365
Open AccessThe Relationship Between Serum Vitamin D Levels and the First-Attempt Success of the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo (PC-BPPV)
Background/Objectives: Vitamin D deficiency has been associated with the occurrence and recurrence of benign paroxysmal positional vertigo (BPPV), but its influence on the immediate success of canalith repositioning maneuvers remains uncertain. This study investigated the relationship between serum vitamin D levels and the first-attempt success of the Epley maneuver in patients with posterior canal BPPV (PC-BPPV). Methods: This prospective observational study included 140 consecutive adults with objectively confirmed unilateral PC-BPPV. Serum 25-hydroxyvitamin D levels were measured at presentation before treatment. All patients underwent a standardized Epley maneuver. First-attempt success was defined as complete resolution of positional vertigo and disappearance of positional nystagmus on the Dix–Hallpike test at the one-week follow-up visit. Serum vitamin D levels were analyzed both as a continuous variable and according to laboratory reference ranges: deficiency (p = 0.079), a difference that did not reach statistical significance. In unadjusted exploratory analyses, patients with first-attempt success had significantly higher median serum vitamin D levels than those with treatment failure (52.2 [IQR, 30.0–68.4] vs. 36.8 [IQR, 21.3–66.1] nmol/L, p = 0.029), and success rates numerically increased across the three-tier classification (46.1%, 62.2%, 59.3%), without a clear dose–response pattern, neither the overall comparison (p = 0.208) nor pairwise subgroup comparisons reaching statistical significance. In a multivariable model adjusting for age, sex, and month of enrolment, vitamin D remained independently, though modestly, associated with first-attempt success (adjusted OR 1.14 per 10 nmol/L, 95% CI 1.00–1.29). Conclusions: The pre-specified primary comparison of first-attempt Epley maneuver success between vitamin D-deficient and non-deficient patients did not reach statistical significance, although the point estimate favored higher success in the non-deficient group (OR 1.83, 95% CI 0.93–3.59). An exploratory, initially unadjusted analysis suggested a positive, modest association between serum vitamin D as a continuous variable and first-attempt success; this association persisted after multivariable adjustment (adjusted OR 1.14, 95% CI 1.00–1.29) but did not follow a clear dose–response pattern across categorical vitamin D thresholds. These findings should be regarded as hypothesis-generating rather than establishing a definitive prognostic role for vitamin D, and larger, adequately powered multicenter studies are needed to confirm them.
- Open Access
- 25 February 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Could brain-derived neurotrophic factor, irisin, and peroxisome proliferator-activated receptor-gamma be a pathway in cognitive impairment in schizophrenia?
Previous research has indicated the brain-derived neurotrophic factor (BDNF) level is lower in schizophrenia and associated with cognitive impairment. Irisin-BDNF axis may strengthen learning and memory functions. This study examined associations between BDNF, peroxisome proliferator-activated receptor-gamma (PPAR gamma) and irisin with cognitive deficits in schizophrenia. We enrolled 80 patients with schizophrenia and 80 healthy controls (HCs). The enzyme-linked immunosorbent assay (ELISA) method was used for biochemical analysis. The Stroop Test, Trail Making Test (TMT), and Verbal Fluency Test (VFT) were used for cognitive assessment. Statistical analyses included t-tests, correlations, and analysis of covariance (ANCOVA) controlling key confounders. In unadjusted analyses, patients had significantly lower BDNF and PPARγ levels than HCs (ps < 0.001). After controlling for covariates, the difference in BDNF was still significant (F = 11804.71, p < 0.001, partial η² = 0.989), but not for PPARγ (F = 1.32, p = 0.252, partial η² = 0.010). Irisin levels did not differ between groups. Patients performed worse on all cognitive tests. After adjustments, deficits in processing speed (TMT-A, F = 4.30, p = 0.040) and executive function (Stroop-3, F = 5.89, p = 0.016; Stroop-4, F = 6.54, p = 0.012) remained significant. Longer illness duration correlated with lower BDNF (r=-0.318, p < 0.01), while more severe negative symptoms correlated with lower irisin (r=-0.244, p < 0.05). No biomarkers-cognition correlations were found groups separately. Exploratory analyses in the combined sample suggested nominal associations, but these did not survive correction for multiple comparisons and controlling for diagnostic group status. BDNF demonstrates the most robust association with schizophrenia and cognitive function. The association of PPARγ with schizophrenia is confounded by demographic and metabolic factors, and irisin showed a limited link only to negative symptoms. Not applicable.
- 25 February 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessCould brain-derived neurotrophic factor, irisin, and peroxisome proliferator-activated receptor-gamma be a pathway in cognitive impairment in schizophrenia?
Previous research has indicated the brain-derived neurotrophic factor (BDNF) level is lower in schizophrenia and associated with cognitive impairment. Irisin-BDNF axis may strengthen learning and memory functions. This study examined associations between BDNF, peroxisome proliferator-activated receptor-gamma (PPAR gamma) and irisin with cognitive deficits in schizophrenia. We enrolled 80 patients with schizophrenia and 80 healthy controls (HCs). The enzyme-linked immunosorbent assay (ELISA) method was used for biochemical analysis. The Stroop Test, Trail Making Test (TMT), and Verbal Fluency Test (VFT) were used for cognitive assessment. Statistical analyses included t-tests, correlations, and analysis of covariance (ANCOVA) controlling key confounders. In unadjusted analyses, patients had significantly lower BDNF and PPARγ levels than HCs (ps < 0.001). After controlling for covariates, the difference in BDNF was still significant (F = 11804.71, p < 0.001, partial η² = 0.989), but not for PPARγ (F = 1.32, p = 0.252, partial η² = 0.010). Irisin levels did not differ between groups. Patients performed worse on all cognitive tests. After adjustments, deficits in processing speed (TMT-A, F = 4.30, p = 0.040) and executive function (Stroop-3, F = 5.89, p = 0.016; Stroop-4, F = 6.54, p = 0.012) remained significant. Longer illness duration correlated with lower BDNF (r=-0.318, p < 0.01), while more severe negative symptoms correlated with lower irisin (r=-0.244, p < 0.05). No biomarkers-cognition correlations were found groups separately. Exploratory analyses in the combined sample suggested nominal associations, but these did not survive correction for multiple comparisons and controlling for diagnostic group status. BDNF demonstrates the most robust association with schizophrenia and cognitive function. The association of PPARγ with schizophrenia is confounded by demographic and metabolic factors, and irisin showed a limited link only to negative symptoms. Not applicable.
- Open Access
- 11 April 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (3) , 334-343
Frequency and pattern of test utilization rate in clinical biochemistry laboratory: two different large hospital examples
Objectives: Clinical biochemistry laboratories (CBL) are the most frequently utilized laboratory group in healthcare, and their significance in patient care is indisputable. This study investigated the frequency and pattern of test utilization rate in CBL at two large hospitals’ outpatient and inpatient clinics. Methods: A total of 43,732,428 CBL tests, including clinical chemistry, immunoassay, coagulation, specific proteins, CBC, and urinalysis, were conducted for 12,182,382 patients across two large hospitals in different settings between 2018 and 2022. These tests were analyzed alongside patient admissions data, with a focus on the distribution across various clinics. Results: A total of 94 % and 93 % of those admitted to Hospitals 1 and 2 were outpatients. They had applied to CBL laboratories for 27.1–30.3 % of outpatients and 81.2–88.7 % of inpatients for at least one test. When analyzing the rates at which laboratory tests were requested for outpatients, it was found that emergency departments had the highest test-requesting rates, ranging from 19.99 to 45.36 %. This was followed by internal medicine clinics, with rates ranging from 13.77 to 14.8 %, and inpatient intensive care units, with rates between 24.31 and 30.14 %. Outpatients had 10–11 test requests for each patient and 16–31 for inpatients. The most frequently requested laboratory tests were CBC, glucose, creatinine, urea, AST and ALT in two hospitals. Conclusions: Despite significant variations in location, structure, medical staff, and patient demographics, approximately one-third of outpatients and 85 % of inpatients at these hospitals undergo testing in CBL. CBLs are essential for screening, diagnosis, prognosis, and healthcare treatment.
- 11 April 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (3) , 334-343
Open AccessFrequency and pattern of test utilization rate in clinical biochemistry laboratory: two different large hospital examples
Objectives: Clinical biochemistry laboratories (CBL) are the most frequently utilized laboratory group in healthcare, and their significance in patient care is indisputable. This study investigated the frequency and pattern of test utilization rate in CBL at two large hospitals’ outpatient and inpatient clinics. Methods: A total of 43,732,428 CBL tests, including clinical chemistry, immunoassay, coagulation, specific proteins, CBC, and urinalysis, were conducted for 12,182,382 patients across two large hospitals in different settings between 2018 and 2022. These tests were analyzed alongside patient admissions data, with a focus on the distribution across various clinics. Results: A total of 94 % and 93 % of those admitted to Hospitals 1 and 2 were outpatients. They had applied to CBL laboratories for 27.1–30.3 % of outpatients and 81.2–88.7 % of inpatients for at least one test. When analyzing the rates at which laboratory tests were requested for outpatients, it was found that emergency departments had the highest test-requesting rates, ranging from 19.99 to 45.36 %. This was followed by internal medicine clinics, with rates ranging from 13.77 to 14.8 %, and inpatient intensive care units, with rates between 24.31 and 30.14 %. Outpatients had 10–11 test requests for each patient and 16–31 for inpatients. The most frequently requested laboratory tests were CBC, glucose, creatinine, urea, AST and ALT in two hospitals. Conclusions: Despite significant variations in location, structure, medical staff, and patient demographics, approximately one-third of outpatients and 85 % of inpatients at these hospitals undergo testing in CBL. CBLs are essential for screening, diagnosis, prognosis, and healthcare treatment.
- Open Access
- 18 January 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 316 (2) , 1-4
Can the mucosal attacks of Behçet’s disease be predicted?
The primary objective of this study was to investigate the association between disease activity and serum and salivary procalcitonin (Pct) levels in patients with Behçet’s disease (BD). The study included patients diagnosed with BD and age-matched healthy volunteers (N: 48, N: 32). Serum and salivary Pct levels were quantified using enzyme-linked immunosorbent assay (ELISA) in the laboratories of Diskapi Yildirim Beyazit Training and Research Hospital. No significant disparity was observed in serum and salivary Pct levels between the patient and control groups (p > 0.05). Furthermore, there was no noteworthy correlation between disease activity and serum and salivary Pct values (p > 0.05). However, the serum Pct level in patients with active oral ulcers was significantly elevated compared to those without active oral ulcers (p: 0.003). Serum Pct emerges as a valuable marker for monitoring oral aphthous ulcer attacks within the patient population.
- 18 January 2024
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 316 (2) , 1-4
Open AccessCan the mucosal attacks of Behçet’s disease be predicted?
The primary objective of this study was to investigate the association between disease activity and serum and salivary procalcitonin (Pct) levels in patients with Behçet’s disease (BD). The study included patients diagnosed with BD and age-matched healthy volunteers (N: 48, N: 32). Serum and salivary Pct levels were quantified using enzyme-linked immunosorbent assay (ELISA) in the laboratories of Diskapi Yildirim Beyazit Training and Research Hospital. No significant disparity was observed in serum and salivary Pct levels between the patient and control groups (p > 0.05). Furthermore, there was no noteworthy correlation between disease activity and serum and salivary Pct values (p > 0.05). However, the serum Pct level in patients with active oral ulcers was significantly elevated compared to those without active oral ulcers (p: 0.003). Serum Pct emerges as a valuable marker for monitoring oral aphthous ulcer attacks within the patient population.
- Open Access
- 20 December 2023
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (2) , 187-196
Flow cytometric analysis of lymphocyte subsets, monocytes, and HLA-DR expressions on these cells in patients with COVID-19
Objectives: We aimed to investigate the lymphocyte subsets and monocytes by flow cytometry and the correlations between their HLA-DR expressions and inflammatory markers in patients with COVID-19. Methods: The study included 49 patients with COVID-19 and 42 healthy controls. Blood samples were taken into EDTA tubes. WBC counts were analyzed by the Sysmex/XN-1000i device, and lymphocyte subsets and monocytes were analyzed by flow cytometry. The percentage of HLA-DR expression on cells and median fluorescence intensity (MFI) values were recorded to detect activation. Lymphocyte counts were calculated using the dual-platform method. Correlations between antigen expression and ferritin, CRP, and D-dimer levels were analyzed. Results: The patient group had lower WBC and lymphocyte counts but significantly higher monocyte counts and neutrophil/lymphocyte ratios compared to controls (p=0.009, p=0.045, respectively). The patient group had significantly lower T lymphocyte counts (p=0.008). B lymphocyte counts and percentages were lower (p+ monocytes were significantly increased in the patient group (p=0.001, p=0.004, p+ monocytes in COVID-19.
- 20 December 2023
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (2) , 187-196
Open AccessFlow cytometric analysis of lymphocyte subsets, monocytes, and HLA-DR expressions on these cells in patients with COVID-19
Objectives: We aimed to investigate the lymphocyte subsets and monocytes by flow cytometry and the correlations between their HLA-DR expressions and inflammatory markers in patients with COVID-19. Methods: The study included 49 patients with COVID-19 and 42 healthy controls. Blood samples were taken into EDTA tubes. WBC counts were analyzed by the Sysmex/XN-1000i device, and lymphocyte subsets and monocytes were analyzed by flow cytometry. The percentage of HLA-DR expression on cells and median fluorescence intensity (MFI) values were recorded to detect activation. Lymphocyte counts were calculated using the dual-platform method. Correlations between antigen expression and ferritin, CRP, and D-dimer levels were analyzed. Results: The patient group had lower WBC and lymphocyte counts but significantly higher monocyte counts and neutrophil/lymphocyte ratios compared to controls (p=0.009, p=0.045, respectively). The patient group had significantly lower T lymphocyte counts (p=0.008). B lymphocyte counts and percentages were lower (p+ monocytes were significantly increased in the patient group (p=0.001, p=0.004, p+ monocytes in COVID-19.
- 30 August 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (2) , 083-090
The Need for Assay Harmonization: Carbohydrate Antigen 19-9 (CA 19-9) Assay Example
Amaç: CA 19-9, yüksek riskli kişilerde pankreas, safra kanalı ve kolon kanserlerinin tespiti ve takibinde diğer testlerin tamamlayıcısı olarak yaygın kullanılan bir biyobelirteçtir. CA 19-9 testinin farklı yöntemlerle ölçüm sonuçları arasında uyumsuzluklar bulunabilmektedir. Bu çalışmanın amacı CA 19-9 testinin harmonizasyon problemini ortaya koymaktır. Gereç ve Yöntemler: Randox Uluslararası Kalite Değerlendirme Programı tarafından sağlanan 2018 yılına ait dış kalite değerlendirme programına göre, üç farklı seviyede CA 19-9 içeren dış kalite kontrol serum örneklerinin sonuçları değerlendirildi. Abbott Architect, Beckman Access DXI600/800, Roche Cobas 6000/8000 ve Siemens Advia Centaur XP/XPT/Classic cihazlarına ait sonuçlar karşılaştırıldı. Bulgular: Dış kalite kontrol programından elde edilen verilere göre, aynı numune için farklı cihazlardan elde edilen CA 19-9 test sonuçları arasında bir uyum tespit edilememiştir. Dört sistemin her birine ait peer grup ortalamaları ve laboratuvarlararası CV’ler oldukça farklılık göstermektedir. Genel olarak, en yüksek peer grup ortalama değerleri Abbott Architect sistemi, bunu takiben Siemens Centaur XP/XPT/Classic sisteminden ve en düşük peer grup ortalamaları ise Roche Cobas sisteminden elde edilmiştir. Laboratuvarlararası % CV 4.5-10.1 arasında değişen geniş bir aralık göstermektedir. Sonuç: Bulgularımıza göre, dört farklı sistem kullanılarak elde edilen CA 19-9 sonuçlarının harmonizasyonunun henüz sağlanamadığı görülmüştür. Farklı üreticilere ait kitlerle ölçülen CA 19-9 konsantrasyonları sistematik farklılıklar(farklı antikor kullanımı vb.) nedeniyle varyasyon gösterebilir. Sonuç olarak, CA 19-9 düzeyini ölçmede kullanılan kit/yöntemin laboratuvar sonuç raporunda belirtilmesinin faydalı olacağını düşünüyoruz.
- 30 August 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (2) , 083-090
The Need for Assay Harmonization: Carbohydrate Antigen 19-9 (CA 19-9) Assay Example
Amaç: CA 19-9, yüksek riskli kişilerde pankreas, safra kanalı ve kolon kanserlerinin tespiti ve takibinde diğer testlerin tamamlayıcısı olarak yaygın kullanılan bir biyobelirteçtir. CA 19-9 testinin farklı yöntemlerle ölçüm sonuçları arasında uyumsuzluklar bulunabilmektedir. Bu çalışmanın amacı CA 19-9 testinin harmonizasyon problemini ortaya koymaktır. Gereç ve Yöntemler: Randox Uluslararası Kalite Değerlendirme Programı tarafından sağlanan 2018 yılına ait dış kalite değerlendirme programına göre, üç farklı seviyede CA 19-9 içeren dış kalite kontrol serum örneklerinin sonuçları değerlendirildi. Abbott Architect, Beckman Access DXI600/800, Roche Cobas 6000/8000 ve Siemens Advia Centaur XP/XPT/Classic cihazlarına ait sonuçlar karşılaştırıldı. Bulgular: Dış kalite kontrol programından elde edilen verilere göre, aynı numune için farklı cihazlardan elde edilen CA 19-9 test sonuçları arasında bir uyum tespit edilememiştir. Dört sistemin her birine ait peer grup ortalamaları ve laboratuvarlararası CV’ler oldukça farklılık göstermektedir. Genel olarak, en yüksek peer grup ortalama değerleri Abbott Architect sistemi, bunu takiben Siemens Centaur XP/XPT/Classic sisteminden ve en düşük peer grup ortalamaları ise Roche Cobas sisteminden elde edilmiştir. Laboratuvarlararası % CV 4.5-10.1 arasında değişen geniş bir aralık göstermektedir. Sonuç: Bulgularımıza göre, dört farklı sistem kullanılarak elde edilen CA 19-9 sonuçlarının harmonizasyonunun henüz sağlanamadığı görülmüştür. Farklı üreticilere ait kitlerle ölçülen CA 19-9 konsantrasyonları sistematik farklılıklar(farklı antikor kullanımı vb.) nedeniyle varyasyon gösterebilir. Sonuç olarak, CA 19-9 düzeyini ölçmede kullanılan kit/yöntemin laboratuvar sonuç raporunda belirtilmesinin faydalı olacağını düşünüyoruz.
- Open Access
- 3 June 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (4) , 459-465
The evaluation of pancreas β-cell autoantibodies in non-diabetic COVID-19 patients
Objective: This study aims to evaluate potential pancreas endocrine damage due to SARS-CoV-2 by measuring β-cell autoantibodies in COVID-19 patients. Subjects and methods: Between June and July 2020, 95 inpatients with a positive COVID-19 test result after polymerase-chain-reaction (PCR) and who met the inclusion criteria were enrolled in our study. Laboratory parameters that belong to glucose metabolism and β-cell autoantibodies, including anti-islet, anti-glutamic acid decarboxylase, and anti-insulin autoantibodies, were measured. β-cell autoantibodies levels of the patients were measured during [...] ABSTRACT Objective: This study aims to evaluate potential pancreas endocrine damage due to SARS-CoV-2 by measuring β-cell autoantibodies in COVID-19 patients. Subjects and methods: Between June and July 2020, 95 inpatients with a positive COVID-19 test result after polymerase-chain-reaction (PCR) and who met the inclusion criteria were enrolled in our study. Laboratory parameters that belong to glucose metabolism and β-cell autoantibodies, including anti-islet, anti-glutamic acid decarboxylase, and anti-insulin autoantibodies, were measured. β-cell autoantibodies levels of the patients were measured during
- 3 June 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (4) , 459-465
Open AccessThe evaluation of pancreas β-cell autoantibodies in non-diabetic COVID-19 patients
Objective: This study aims to evaluate potential pancreas endocrine damage due to SARS-CoV-2 by measuring β-cell autoantibodies in COVID-19 patients. Subjects and methods: Between June and July 2020, 95 inpatients with a positive COVID-19 test result after polymerase-chain-reaction (PCR) and who met the inclusion criteria were enrolled in our study. Laboratory parameters that belong to glucose metabolism and β-cell autoantibodies, including anti-islet, anti-glutamic acid decarboxylase, and anti-insulin autoantibodies, were measured. β-cell autoantibodies levels of the patients were measured during [...] ABSTRACT Objective: This study aims to evaluate potential pancreas endocrine damage due to SARS-CoV-2 by measuring β-cell autoantibodies in COVID-19 patients. Subjects and methods: Between June and July 2020, 95 inpatients with a positive COVID-19 test result after polymerase-chain-reaction (PCR) and who met the inclusion criteria were enrolled in our study. Laboratory parameters that belong to glucose metabolism and β-cell autoantibodies, including anti-islet, anti-glutamic acid decarboxylase, and anti-insulin autoantibodies, were measured. β-cell autoantibodies levels of the patients were measured during
- Open Access
- 11 May 2022
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (5) , 557-563
Verification of enzymatic ethanol analysis method and method comparison with headspace gas chromatography
Objectives: This study aimed to verify the enzymatic ethanol analysis method and compare the technique with headspace gas chromatography (HS/GC). Methods: The limit of the blank, limit of detection, and limit of quantification, precision, linearity, and accuracy of the enzymatic process were evaluated based on the data obtained. In addition, a method comparison was made between the enzymatic method and the HS/GC analysis method. Results: It was seen that the enzymatic method was linear in the range of 14–450 mg/dL, the coefficient of variation and bias values ranged between 0.5–1.09% and 4.52–9.78%, respectively. The quantitative accuracy was 2.13% and 2.23% at concentrations of 41.16 and 95.82 mg/dL, respectively. When the regression analysis was performed between the results obtained using the enzymatic alcohol dehydrogenase (ADH) and HS/GC methods, y=0.966x + 2.084 linear relationship formula and regression coefficient of r 2 =0.9987, it was found that it showed a good agreement at a confidence interval of 5%. Conclusions: The findings showed that the enzymatic method had good linearity, excellent precision, and a high correlation with the higher-order comparator method, the HS/GC method, in the ethanol analysis.
- 11 May 2022
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (5) , 557-563
Open AccessVerification of enzymatic ethanol analysis method and method comparison with headspace gas chromatography
Objectives: This study aimed to verify the enzymatic ethanol analysis method and compare the technique with headspace gas chromatography (HS/GC). Methods: The limit of the blank, limit of detection, and limit of quantification, precision, linearity, and accuracy of the enzymatic process were evaluated based on the data obtained. In addition, a method comparison was made between the enzymatic method and the HS/GC analysis method. Results: It was seen that the enzymatic method was linear in the range of 14–450 mg/dL, the coefficient of variation and bias values ranged between 0.5–1.09% and 4.52–9.78%, respectively. The quantitative accuracy was 2.13% and 2.23% at concentrations of 41.16 and 95.82 mg/dL, respectively. When the regression analysis was performed between the results obtained using the enzymatic alcohol dehydrogenase (ADH) and HS/GC methods, y=0.966x + 2.084 linear relationship formula and regression coefficient of r 2 =0.9987, it was found that it showed a good agreement at a confidence interval of 5%. Conclusions: The findings showed that the enzymatic method had good linearity, excellent precision, and a high correlation with the higher-order comparator method, the HS/GC method, in the ethanol analysis.
- Open Access
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 677-682
Could Irisin Levels be Affected by Physical Activity in Patients with Schizophrenia?
Gamze Erzin, Olga Güriz, Ali Yalçındağ, Akfer Kahıloğulları, Sibel Örsel. Clin Psychopharmacol Neurosci 2021;19:677-82. https://doi.org/10.9758/cpn.2021.19.4.677
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 677-682
Open AccessCould Irisin Levels be Affected by Physical Activity in Patients with Schizophrenia?
Gamze Erzin, Olga Güriz, Ali Yalçındağ, Akfer Kahıloğulları, Sibel Örsel. Clin Psychopharmacol Neurosci 2021;19:677-82. https://doi.org/10.9758/cpn.2021.19.4.677
- Open Access
- 3 September 2021
- Published by Hacettepe University - Medical School in Acta Medica
- p. 1-6
Analytical Process Evaluation of Biochemistry Laboratory by Using Six Sigma Method
Objectives: The primary purpose of medical laboratories is to provide the most accurate results appropriate to the patient's medical condition. Therefore, the reliability of each laboratory must be scientifically tested. Approximately 10% of laboratory errors occur in the analytical phase. In this study, we aimed to evaluate analytical process performances of 14 routinely assayed parameters according to six sigma methodology. Materials and Methods: Mean, standard deviation and coefficient of variation were calculated from internal quality control data for three months from 14 routinely assayed parameters (albumin, alanine aminotransferase, aspartate aminotransferase, chloride, creatinine, glucose, HDL cholesterol, lactate dehydrogenase, potassium, total cholesterol, total protein, sodium, triglyceride and urea) in the laboratory (Roche Cobas c501). Bias was calculated using external quality control values for same months. Total error was also calculated. Acceptable total error was determined according to the Clinical Laboratory Improvement Amendments and Turkey criteria. Sigma values were calculated and divided into four groups; as 6 world-class performance. Results: According to the Clinical Laboratory Improvement Amendments and Turkey sigma assessment, first levels of chloride, total cholesterol, glucose and urea performance were unacceptable. Moreover according to the Clinical Laboratory Improvement Amendments sigma assessment, first levels of albumin, creatinine, total protein; and both levels of sodium, chloride and urea were unacceptable. Other tests were found to be suited for purpose, acceptable or world-class performance. Conclusions: Sigma measurements should be routinely performed in laboratories for evaluating the analytical period performance of the laboratory. That will increase its quality via regulatory preventive actions. Our study allowed us to see and improve our measurement quality by determining the three-month periodic performance of our laboratory tests.
- 3 September 2021
- Published by Hacettepe University - Medical School in Acta Medica
- p. 1-6
Open AccessAnalytical Process Evaluation of Biochemistry Laboratory by Using Six Sigma Method
Objectives: The primary purpose of medical laboratories is to provide the most accurate results appropriate to the patient's medical condition. Therefore, the reliability of each laboratory must be scientifically tested. Approximately 10% of laboratory errors occur in the analytical phase. In this study, we aimed to evaluate analytical process performances of 14 routinely assayed parameters according to six sigma methodology. Materials and Methods: Mean, standard deviation and coefficient of variation were calculated from internal quality control data for three months from 14 routinely assayed parameters (albumin, alanine aminotransferase, aspartate aminotransferase, chloride, creatinine, glucose, HDL cholesterol, lactate dehydrogenase, potassium, total cholesterol, total protein, sodium, triglyceride and urea) in the laboratory (Roche Cobas c501). Bias was calculated using external quality control values for same months. Total error was also calculated. Acceptable total error was determined according to the Clinical Laboratory Improvement Amendments and Turkey criteria. Sigma values were calculated and divided into four groups; as 6 world-class performance. Results: According to the Clinical Laboratory Improvement Amendments and Turkey sigma assessment, first levels of chloride, total cholesterol, glucose and urea performance were unacceptable. Moreover according to the Clinical Laboratory Improvement Amendments sigma assessment, first levels of albumin, creatinine, total protein; and both levels of sodium, chloride and urea were unacceptable. Other tests were found to be suited for purpose, acceptable or world-class performance. Conclusions: Sigma measurements should be routinely performed in laboratories for evaluating the analytical period performance of the laboratory. That will increase its quality via regulatory preventive actions. Our study allowed us to see and improve our measurement quality by determining the three-month periodic performance of our laboratory tests.